| Literature DB >> 29056892 |
Jinmei Wang1,2, Pengli Lian1, Qi Yu1, Jinfeng Wei1,2, Wenyi Kang1,2.
Abstract
The blackberry seed was typically removed as a byproduct and waste from blackberry fruits for juices. Developing value-added utilization of berry seeds will significantly expand the market for berry products as well as improve benefit to berry producers. However, the research on blackberry seed is limited. The objective of this paper was to research antithrombotic mechanism of polysaccharides in blackberry seeds. Polysaccharides in blackberry seeds were extracted, purified and identified by high-performance gel permeation chromatography (HPSEC), gas chromatography (GC), fourier transform infrared (FT-IR) spectrometer and nuclear magnetic resonance spectra (NMR). Anticoagulant activities were evaluated in vivo by measuring activated partial thromboplastin time (APTT), thrombin time (TT), prothrombin time (PT), fibrinogen (FIB) and plasma recalcification time (RRT). Four polysaccharides named BSP-1a, BSP-1b, BSP-2 and BSP-3 were isolated from Blackberry (Rubus spp.) seeds. The results indicated that BSP-1b, BSP-2 and BSP-3 exhibited the anticoagulant activity. Therefore, the anti-thrombosis effects of BSP-1b, BSP-2 and BSP-3 were investigated in vivo by 6-Keto-PGF1α, thromboxane B2 (TXB2), endothelial nitric oxide synthase (eNOS), endothelin-1 (ET-1), whole blood viscosity (WBV), plasma viscosity (PV), hematocrit (Hct), erythrocyte sedimentation rate (ESR), APTT, TT, PT and FIB. The results suggested that BSP-1b, BSP-2 and BSP-3 had the inhibition effect on thrombus formation, and the antithrombotic effects were associated with the regulation of vascular endothelium active substance, activating blood flow and anticoagulation effect.Entities:
Keywords: Blackberry seed; anticoagulant; antithrombotic; polysaccharides; structural
Year: 2017 PMID: 29056892 PMCID: PMC5642186 DOI: 10.1080/16546628.2017.1379862
Source DB: PubMed Journal: Food Nutr Res ISSN: 1654-661X Impact factor: 3.894
Figure 1.Infrared spectra of BSP-1a, BSP-1b, BSP-2 and BSP-3.
Figure 2.1H NMR spectrum of BSP-1a (a), BSP-1b (b), BSP-2 (c) and BSP-3 (d).
Anticoagulation activity of BSP-1a, BSP-1b, BSP-2 and BSP-3.
| Group | PRT(s) | APTT(S) | PT(S) | TT(s) | FIB(g/L) |
|---|---|---|---|---|---|
| blank | 219.7 ± 3.2 | 20.50 ± 0.08 | 9.93 ± 0.10 | 32.78 ± 0.10 | 3.38 ± 0.02 |
| breviscapine | 274.5 ± 5.2### | 32.73 ± 0.13### | 10.95 ± 0.06### | 39.55 ± 0.13### | 5.29 ± 0.17### |
| vitamin k1 | 164.1 ± 2.0### | 13.53 ± 0.13### | 7.55 ± 0.06### | 19.67 ± 0.17### | — |
| BPS-1a | 237.7 ± 3.7###ΔΔΔ | 15.68 ± 0.13###ΔΔΔ | 8.63 ± 0.15###ΔΔΔ | 31.25 ± 0.06###ΔΔΔ | 3.83 ± 0.12###*** |
| BPS-1b | 342.0 ± 4.9###*** | 45.70 ± 0.08###*** | 10.45 ± 0.42##** | 53.20 ± 1.40###*** | 3.41 ± 0.09#*** |
| BPS-2 | 318.8 ± 3.8###*** | 24.15 ± 0.06###*** | 9.90 ± 0.14# | 39.65 ± 1.43###* | 3.12 ± 0.14###*** |
| BPS-3 | 352.8 ± 8.8###*** | 28.30 ± 0.08###*** | 10.83 ± 0.15###* | 61.50 ± 3.05###*** | 2.65 ± 0.10###*** |
Compared with Blank (0.01 < *P < 0.05, 0.001<**P < 0.01, *** P < 0.001);
Compared with Breviscapine (0.01 <# P < 0.05, 0.001<## P < 0.01, ### P < 0.001).
Compared with Vitamin k1 (0.01 < Δ P < 0.05, 0.001 < ΔΔ P < 0.01, ΔΔΔ P < 0.001).
Figure 3.Effect on 6-keto-PGE1α and TXB2 in rats.
(n = 6, ### P < 0.001, # P < 0.05 vs. control; *** P < 0.001 vs. model).
Figure 4.Effect on ET-1 in rats.
(n = 6, ### P < 0.001vs. control, *** P < 0.001 vs. model).
Figure 5.Effect on eNOS in rats.
(n = 6, ### P < 0.001vs. control, *** P < 0.001 vs. model).
Effect on WBV and Hct.
| WBV(mPa·s) | |||||
|---|---|---|---|---|---|
| Group | Dose (mg/kg) | 200/s | 20/s | 3/s | Hct(%) |
| Blank | – | 3.54 ± 0.31 | 4.60 ± 0.29 | 9.23 ± 0.13 | 37.85 ± 0.93 |
| Model | – | 4.28 ± 0.23### | 5.94 ± 0.35### | 11.11 ± 0.35### | 41.96 ± 0.91### |
| Aspirin | 100 | 3.83 ± 0.37Δ | 4.78 ± 0.46ΔΔΔ | 9.53 ± 0.19ΔΔΔ | 39.62 ± 0.78ΔΔ |
| BSP-1b | 120 | 3.80 ± 0.32Δ | 5.12 ± 0.14ΔΔΔ | 9.94 ± 0.44ΔΔΔ | 39.58 ± 1.36ΔΔ |
| BSP-2 | 120 | 3.89 ± 0.20Δ | 5.08 ± 0.15ΔΔΔ | 10.34 ± 0.60Δ | 39.42 ± 1.56ΔΔ |
| BSP-3 | 120 | 3.91 ± 0.29Δ | 5.30 ± 0.24ΔΔ | 10.24 ± 0.79Δ | 40.12 ± 0.62Δ |
Data represent mean ± SD. n = 6;
Compared with blank (### P < 0.001)
Compared with model (ΔΔΔ P < 0.001, 0.01 < ΔΔ P<0.01, Δ P 0.05)
Compared with aspirin (0.001 < ** P < 0.01, * P < 0.05)
Effect on ESR and PV.
| Group | Dose (mg/kg) | ESR (mm/h) | PV (mPa·s) |
|---|---|---|---|
| Blank | – | 3 ± 0.82 | 1.36 ± 0.06 |
| Model | – | 11.5 ± 1.29### | 1.53 ± 0.09## |
| aspirin | 100 | 7 ± 0.82ΔΔΔ | 1.39 ± 0.04ΔΔ |
| BSP-1b | 120 | 4.25 ± 0.95ΔΔΔ | 1.38 ± 0.07ΔΔ |
| BSP-2 | 120 | 7.25 ± 1.7ΔΔΔ | 1.36 ± 0.09ΔΔ |
| BSP-3 | 120 | 8.5 ± 1.3ΔΔΔ | 1.43 ± 0.05Δ |
Data represent mean ± SD. n = 6;
Compared with blank (### P < 0.001, 0.001<## P < 0.01)
Compared with model (ΔΔΔ P < 0.001, 0.01 < ΔΔ P < 0.01, Δ P< 0.05)
Compared with aspirin (0.001 < ** P < 0.01)
Coagulation parameters of BSP-1a, BSP-1b, BSP-2 and BSP-3.
| Plasma coagulation parameters | |||||
|---|---|---|---|---|---|
| Group | Dose (mg/kg) | APTT(s) | PT(s) | TT(s) | FIB(g/L) |
| blank | – | 44.45 ± 1.87 | 23.4 ± 0.53 | 36.05 ± 1.37 | 2.3 ± 0.12 |
| model | – | 23.88 ± 1.21### | 18.62 ± 0.55### | 18.58 ± 0.62### | 3.9 ± 0.22### |
| aspirin | 100 | 34.47 ± 0.63ΔΔΔ | 20.5 ± 0.52ΔΔΔ | 32.8 ± 1.11ΔΔΔ | 3.44 ± 0.13ΔΔΔ |
| BSP-1b | 120 | 39.85 ± 1.89ΔΔΔ | 24.53 ± 0.39ΔΔΔ | 28.25 ± 0.99ΔΔΔ | 3.72 ± 0.14 |
| BSP-2 | 120 | 37.19 ± 1.21ΔΔΔ | 26.48 ± 0.92ΔΔΔ | 29.35 ± 1.06ΔΔΔ | 3.22 ± 0.23ΔΔΔ |
| BSP-3 | 120 | 38.93 ± 0.83ΔΔΔ | 27.38 ± 0.79ΔΔΔ | 29.4 ± 0.48ΔΔΔ | 2.83 ± 0.11ΔΔΔ |
Data represent mean ± SD. n = 6;
Compare with Blank (### P < 0.001, 0.001<# P < 0.05)
Compare with model (ΔΔΔ P < 0.001)
Compare with aspirin (*** P < 0.001, * P < 0.05)